INTRODUCTION
============

*Helicobacter pylori* (*H. pylori*) requires iron to survive and may potentially be associated with unexplained iron-deficiency anemia (IDA) \[[@B1]\]. The prevalence of *H. pylori* infection in refractory IDA is higher than in the normal population \[[@B2]\], and an association between low serum ferritin levels and a high prevalence of *H. pylori*-specific IgG has been noted \[[@B3]\]. *H. pylori*-related refractory IDA can be reversed by eradication of *H. pylori* \[[@B4]\], and some *H. pylori*-infected IDA patients achieve normal serum hemoglobin levels after *H. pylori* eradication, even without oral iron treatment \[[@B5]\]. Additionally, it has been shown that combined *H. pylori* eradication and iron replacement produces a faster response than iron therapy alone \[[@B6]\]. Based on these findings, eradication of *H. pylori* is recommended in unexplained IDA patients \[[@B7]\], although no association between the pathogenesis of IDA and *H. pylori* infection has yet been established. A key pathogenic connection must exist to explain the relationship between *H. pylori* infection and IDA, as not all *H. pylori*-infected patients develop unexplained IDA.

Hepcidin, a 25-amino-acid disulfide-rich peptide that is synthesized in the liver, acts as a systemic iron regulatory hormone and plays an important role in duodenal iron absorption \[[@B8]\]. Hepcidin mRNA is induced by interleukin-6 \[[@B9]\], and its expression is enhanced by factors such as lipopolysaccharides and *Streptococcus iniae* infection \[[@B10]\]. Hepcidin binds to cell-surface ferroportin to trigger its tyrosine phosphorylation, internalization, and ubiquitin-mediated degradation in lysosomes, resulting in the retention of iron in enterocytes and the interruption of iron release from macrophages \[[@B11]\]. In murine models, parenchymal iron deposition has been reported in hepcidin knockout mice \[[@B12]\], whereas transgenic mice that overexpress hepcidin exhibited decreased body iron levels and presented with severe IDA \[[@B13]\]. Additionally, *H. pylori* subverts the human iron regulatory mechanism in a manner that is beneficial to *H. pylori*, but deleterious to the host, by inducing the up-regulation of hepcidin and/or down-regulation of ferroportin \[[@B14]\].

Attempts to produce correctly folded synthetic hepcidin have proved difficult. Thus, prohepcidin, the 60-amino acid product of the cleavage of the signal peptide from the hepcidin precursor, is measured with a currently available commercial assay for bioactive hepcidin analysis \[[@B15]\]. To determine the feasibility of serum prohepcidin as a useful biomarker in IDA, it is first necessary to determine the precise molecular mechanism underlying the action of prohepcidin under various conditions. In this study, we evaluated changes in serum prohepcidin levels before and after *H. pylori* eradication in *H. pylori*-infected IDA patients to establish whether it normalized after treatment.

METHODS
=======

Patients
--------

Subjects diagnosed with unexplained IDA at the Division of Hematology at Konkuk University Medical Center between October 2006 and March 2008 were asked to participate in the study. Upper gastrointestinal endoscope and colonoscope examinations were performed to exclude any source of gastrointestinal bleeding. Other exclusion criteria were: 1) patients with chronic inflammatory disease, infection, recent bleeding, or malignancy, 2) subjects who had previously undergone *H. pylori* eradication, or 3) subjects who had taken regular iron supplement therapy within the most recent 3 months.

Blood was sampled before treatment to eradicate *H. pylori* and again 1 month later for hemoglobin, hematocrit, iron (Fe), total iron binding capacity (TIBC), ferritin, and serum pro-hepcidin levels.

Blood was sampled before treatment to eradicate *H. pylori* and again 1 month later for hemoglobin, hematocrit, iron (Fe), total iron binding capacity (TIBC), ferritin, and serum pro-hepcidin levels.

Diagnosis and treatment for *H. pylori* infection
-------------------------------------------------

Positivity for *H. pylori* infection was recorded when one of the following tests was positive: 1) histology with hematoxylin and eosin staining and Giemsa staining, 2) rapid urease by a CLOtest, or 3) a serum antibody test. For the first eradication, amoxicillin 1 g, clarithromycin 500 mg, and a proton pump inhibitor 20 mg were given twice a day for 7 days. Four weeks after eradication, a urease breath test was carried out; if it was positive, a second eradication was performed with tetracycline 500 mg and bismuth 300 mg four times a day, metronidazole 500 mg three times a day, and a proton pump inhibitor twice a day for a week. The urease breath test was performed again after 4 weeks of eradication.

Measurement of serum prohepcidin levels
---------------------------------------

Whole blood samples were centrifuged (2,000 × g, 5 minutes), aliquoted, and kept frozen at -80℃ until assayed. Levels of serum prohepcidin were determined by an enzyme-linked immunosorbent assay based on a competitive principle (DRG International Inc., Mountainside, NJ, USA) according to the manufacturer\'s protocol. Optical densities were read with a Bio-Rad PhDTM system (Bio-Rad Laboratories, Hercules, CA, USA). A standard curve was automatically constructed using a 4parameter logistics curve fit with Bio-Rad PhDTM system (Bio-Rad Laboratories), and the corresponding concentrations of patient samples were calculated from the standard curve. All standards, subject samples, and controls were run in duplicate, and individual samples with a coefficient of variation for paired replicates of more than 15.0% were retested. The reduction ratio was determined by dividing the prohepcidin level after the treatment by the initial prohepcidin level.

Statistical analyses
--------------------

Differences between pre-treatment and post-treatment levels were analyzed using the Wilcoxon signed rank test. Differences between *H. pylori*-infected and noninfected groups were analyzed using the chi-squared test and Student\'s *t* test, and comparisons among three groups were done by analysis of variance (ANOVA). Fe and ferritin were analyzed using the Kruskal-Wallis test and are presented as median values. Age, hemoglobin, hematocrit, TIBC, prohepcidin, and reduction ratio are expressed as means ± standard deviations (SD). All increment and decrement ratios were determined by dividing the serum level after 4 weeks of treatment by the initial serum level before treatment. Analysis of covariance was carried out to compare the changes of prohepcidin levels before and after treatment among the groups. A probability value of *p* \< 0.05 was deemed to indicate statistical significance.

RESULTS
=======

Of the 50 initially enrolled subjects, 12 were excluded because the cause of their IDA was established ([Fig. 1](#F1){ref-type="fig"}). Of the 38 remaining IDA subjects, 29 subjects (76.3%) revealed *H. pylori* infection. Eradication was conducted in these 29 subjects, but six refused to participate in the study after the treatment. Baseline characteristics did not differ between the remaining 23 *H. pylori*-infected subjects (212.9 ± 88.2 ng/mL) and nine non-infected subjects (217.8 ± 56.2 ng/mL, *p* = 0.879, [Table 1](#T1){ref-type="table"}). Of 23 *H. pylori*-infected subjects, six patients preferred to undergo *H. pylori* eradication without iron replacement based on their past experiences of severe adverse effects during iron intake. Thus, only 17 *H. pylori*-infected IDA subjects underwent combined *H. pylori* eradication and iron replacement.

Serum prohepcidin levels before and after treatment
---------------------------------------------------

In the 17 subjects who underwent oral iron therapy with successful *H. pylori* eradication, serum prohepcidin level decreased from 200.8 ± 80.8 ng/mL (mean ± SD) to 170.4 ± 67.6 ng/mL after 4 weeks of treatment (*p* = 0.011). Of the 17 subjects, eradication of *H. pylori* failed with the first-line therapy in two, and thus second-line eradication was conducted. At 4 weeks, all showed negative urease breath tests.

Mean serum prohepcidin levels decreased in the six subjects who underwent *H. pylori* eradication alone (247.2 ± 107.0 ng/mL to 200.1 ± 69.4 ng/mL, *p* = 0.075) and in the nine noninfected subjects who took oral iron therapy alone (217.8 ± 56.2 ng/mL to 188.7 ± 52.4 ng/mL, *p* = 0.086). With regard to the reduction ratio of serum prohepcidin levels after treatment, no significant difference among the groups after treatment (*p* = 0.8936, [Table 2](#T2){ref-type="table"}). Although the reduction ratio value in the *H. pylori* eradication alone group (0.86 ± 0.21) was lower than that in the *H. pylori* eradication group with iron replacement (0.88 ± 0.21) and that in the iron replacement only group (0.88 ± 0.18), the difference was not statistically significant (*p* = 0.8936).

Long-term follow-up after *H. pylori* eradication
-------------------------------------------------

Of the 17 subjects who underwent combined oral iron replacement and *H. pylori* eradication, nine were followed at the outpatient clinic at least for 3 months ([Table 3](#T3){ref-type="table"}). All showed a decrease in serum prohepcidin levels ([Fig. 2](#F2){ref-type="fig"}) with improvement in IDA.

DISCUSSION
==========

In this study, we measured only the serum prohepcidin level because of the difficulty inherent in measuring serum hepcidin. Although we were unable to measure hepatic iron accumulation in each case because that would involve an invasive procedure, our data suggest that serum prohepcidin levels were increased in patients with IDA regardless of the presence of *H. pylori* infection. To our knowledge, this is the first reported study to measure serum prohepcidin levels in IDA patients, comparing levels before and after *H. pylori* eradication with or without iron replacement.

Serum prohepcidin levels decreased significantly in the *H. pylori*-infected IDA patients after combined *H. pylori* eradication and oral iron therapy. Additionally, a tendency toward a decrease in serum prohepcidin levels after *H. pylori* eradication or iron replacement was observed. Our findings may be explained by the suggestion made in previous work that *H. pylori* infection results in the regulation of hepcidin, which prevents a response to oral iron and manipulates the host\'s iron homeostasis to ensure its survival \[[@B14],[@B16]\]. Notably, six *H. pylori*-infected subjects who declined to take oral iron also exhibited a reduction in serum prohepcidin levels after *H. pylori* eradiation. It seems that iron therapy is not required in *H. pylori*-infected IDA patients, as it appears that the IDA can be cured merely by eradicating the *H. pylori* infection \[[@B5]\]. However, serum prohepcidin levels decreased further with combined *H. pylori* eradication and oral iron replacement. This is consistent with a previous study that found that combined *H. pylori* eradication and iron replacement produced a faster response than iron therapy alone \[[@B6]\].

The serum concentration of prohepcidin in Korean female college students has been reported to be 85.1 ± 6.1 ng/mL, with a range of 13.6 to 295.7 mg/mL \[[@B17]\]. Serum prohepcidin levels in our IDA patients were significantly higher than this value, regardless of the presence of *H. pylori* infection. We are unable to explain the lack of difference in serum pro-hepcidin levels between the *H. pylori*-infected and noninfected groups before treatment. We suggest that long-term infection with *H. pylori* leads to homeostasis in IDA patients because most are infected during childhood. Interestingly, serum prohepcidin levels exhibited a tendency to decrease in the noninfected IDA group after oral iron therapy, suggesting that hepcidin is an important mediator of iron homeostasis even in noninfected IDA. During long-term follow-up observation for more than 3 months, the prohepcidin levels in nine subjects decreased further after successful *H. pylori* eradication therapy as IDA improved with continuous oral iron replacement. This indicates that the serum prohepcidin level does not normalize immediately.

Our study has several limitations. First, no long-term follow-up data were gathered in the *H. pylori*-eradication only group or the iron-replacement only group. Second, we did not check intragastric acid levels in each subject, although a possibility of achlorhydria exists due to *H. pylori*-induced chronic pangastritis. Third, most of the subjects were premenopausal women; indeed, only two men were included in the study. Most male subjects were ruled out from unexplained IDA because they showed positive findings in upper or lower gastrointestinal endoscopy.

In summary, our findings suggest that serum prohepcidin levels are related to the severity of IDA, rather than to the presence of *H. pylori* infection, for the following reasons. First, basal serum prohepcidin levels were higher in our IDA patients than reported for normal healthy Koreans regardless of *H. pylori* infection status \[[@B17]\]. Second, serum prohepcidin levels decreased after iron-replacement therapy, even in the noninfected group. Third, during longterm followup after successful *H. pylori* eradication, serum prohepcidin levels decreased further with improvement in the IDA. Fourth, no significant difference in the reduction ratios was found among the three groups, although combined *H. pylori* eradication and iron replacement therapy seemed to have a synergistic effect. Fifth, either *H. pylori* eradication or oral iron administration resulted in decreased serum prohepcidin levels after the treatment, accompanied by IDA improvement. Taken together. Taken together, these findings indicate that the serum concentration of prohepcidin is related to the status of anemia rather than to the current status of *H. pylori* infection in IDA patients, indicating that serum concentration of prohepcidin is a functional measure in IDA.
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![Study flow of the subjects. Of 50 subjects, 12 were excluded because the causes of iron-deficiency anemia were found. Of 29 *Helicobacter pylori* (*H. pylori*)-infected subjects, six did not return after 4 weeks of treatment. Thus, only 23 *H. pylori*-infected subjects and nine non-infected subjects were analyzed. IDA, iron-deficiency anemia.](kjim-25-195-g001){#F1}

![Serum prohepcidin levels measured over a long term follow up period. Of 17 subjects who underwent successful *Helicobacter pylori* eradication and iron replacement therapy, nine were followed for more than 3 months. Serum prohepcidin levels continued to decrease in all nine subjects with improvement in iron-deficiency anemia.](kjim-25-195-g002){#F2}

###### 

Baseline characteristics of the *Helicobacter pylori*-infected and noninfected patients with IDA
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Values are presented as mean ± SD.

IDA, iron-deficiency anemia; Fe, iron; TIBC, total iron binding capacity.

^a^Kruskal-Wallis test.

###### 

Changes in laboratory blood tests before and after 4 weeks of treatment

![](kjim-25-195-i002)

Values are presented as mean ± SD.

Fe, iron; TIBC, total iron binding capacity.

^a^Kruskal-Wallis test.

^b^Decrement ratio is determined by dividing the serum level after 4 weeks of treatment by the initial serum level before treatment.
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Long-term follow-up results of nine subjects after combined *Helicobacter pylori* eradication and iron replacement therapy
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